CLASS II Device recall · Reported 19 Apr 2017 · FDA Enforcement Report

Vidas Estradiol II recalled by BioMerieux

BioMerieux is recalling Vidas Estradiol II, distributed nationwide in the US. The recall was initiated on 17 Mar 2017 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLots 1005081700, 1005172850 & 1005359170
Quantity recalled834 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1801-2017
FDA event ID
76727
Recalling firm
BioMerieux, Marcy L'Etoile, N/A
Classification
Class II
Status
Terminated
Recall initiated
17 Mar 2017
FDA classified
12 Apr 2017
Reported
19 Apr 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

17 Mar 2017Recall initiated by company
12 Apr 2017Classified by FDA+26 days
19 Apr 2017Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Fulvestrant cross reacts with the VIDAS Estradiol II immunoassay and may cause falsely elevated estradiol results in patients treated with Fulvestrant.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

VIDAS Estradiol II, Ref 30431-01, 60 tests The VIDAS Estradiol II (E2 II) assay is intended for use on the instruments of the VIDAS family (VITEK ImmunoDiagnostic Assay System) as an automated quantitative enzyme-linked fluorescent immunoassay (ELFA) to the determination of total estradiol concentration in human serum or plasma (heparin).

Where it was distributed

Nationwide Distribution including AZ, CA, CO, FL, GA, IN, IA, LA, MI, MS, NY, NC, OH, OK, OR, PA, TX, WA

Nationwide ArizonaCaliforniaColoradoFloridaGeorgiaIowaIndianaLouisianaMichiganMississippiNorth CarolinaNew YorkOhioOklahomaOregonPennsylvaniaTexasWashington

Questions about this recall

Why was it recalled?

Fulvestrant cross reacts with the VIDAS Estradiol II immunoassay and may cause falsely elevated estradiol results in patients treated with Fulvestrant.

Which lots are affected?

Lots 1005081700, 1005172850 & 1005359170

Where was it sold?

Nationwide Distribution including AZ, CA, CO, FL, GA, IN, IA, LA, MI, MS, NY, NC, OH, OK, OR, PA, TX, WA

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from BioMerieux

All 476

Other Test Kits & Diagnostics recalls

All 2,656